1. Home
  2. BMBL vs IMMP Comparison

BMBL vs IMMP Comparison

Compare BMBL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bumble Inc.

BMBL

Bumble Inc.

HOLD

Current Price

$3.77

Market Cap

425.0M

Sector

Technology

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.32

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMBL
IMMP
Founded
2014
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
425.0M
58.2M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
BMBL
IMMP
Price
$3.77
$0.32
Analyst Decision
Hold
Hold
Analyst Count
14
3
Target Price
$4.42
$5.50
AVG Volume (30 Days)
3.7M
1.1M
Earning Date
05-06-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$965,658,000.00
N/A
Revenue This Year
N/A
$417.85
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.61
$0.29
52 Week High
$8.63
$3.53

Technical Indicators

Market Signals
Indicator
BMBL
IMMP
Relative Strength Index (RSI) 63.24 14.38
Support Level $3.21 N/A
Resistance Level $3.85 $0.39
Average True Range (ATR) 0.19 0.02
MACD 0.02 0.08
Stochastic Oscillator 97.73 21.27

Price Performance

Historical Comparison
BMBL
IMMP

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: